Compare Neurocrine Biosciences Inc (NBIX) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Tenet Healthcare Corporation — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Tenet Healthcare Corporation trades at $269.36 (market cap $20.86B). The key difference: Tenet Healthcare Corporation is the larger of the two by market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | THC | |
|---|---|---|
Market Cap | $15.77B | $20.86B |
Sector | Health | Health |
52-Week High | $185.50 | $280.77 |
52-Week Low | $123.10 | $161.37 |
Enterprise Value | $15.78B | $31.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Tenet Healthcare (THC) trades at $259.06, down 2.26% today, with a bearish technical signal but strong fundamentals. The stock exhibits robust profitability with an 82.83% gross margin and 53.31% ROE, supported by three consecutive quarterly EPS beats. Recent news includes a $2.0 billion senior notes offering for refinancing and participation in the Wells Fargo Healthcare Conference.
Outlook remains positive given analyst consensus of 81.25% buy ratings and a $281.44 price target, implying 8.6% upside. Risks include debt refinancing execution and healthcare regulatory pressures, but earnings momentum and valuation multiples below industry averages present a compelling opportunity for value investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
